

Date: 13.03.2026

To

BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001
BSE - Code : 532660

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

Sub: Outcome of Board Meeting- reg.

The Board of Directors of the Company at its meeting held on March 13, 2026 inter alia, have approved / resolved/ taken note of the following:

1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 considered and approved the submission of the Un-audited Financial Results (Standalone & Consolidated) for the quarter and Nine Months ending 31st December, 2025 attached herewith;
2. Auditors's Limited Review Report on the Un-audited Financial Results of the Company for the quarter and Nine Months ending 31st December, 2025.

The Board meeting concluded at 21:30 Hrs.
You are requested to take note of the above.

Yours faithfully

For VIVIMED LABS LIMITED

SANTOSH VARALWAR
MANAGING DIRECTOR



Vivimed Labs Limited.

CIN : L02411KA1988PLC009465
Registered Office: #78/A, Kolhar Industrial Area,
Bidar, Karnataka-585 403, India
T+91 (0) 8482-232045, F+91 (0) 8482-232436
Email: info@vivimedlabs.com | www.vivimedlabs.com

Corporate Office:

6-3-866/1/G1, 3rd Floor, GMR Towers,
Greelands, Begumpet, Hyderabad
Telangana-500 016, India.
GSTIN: 36AAACV6060A1ZQ
T 91(0) 40-6608-6608, F+91(0) 40-6608-6699

VIVIMED LABS LIMITED

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2025

Rs. In Million

Sl. No.	Particulars	3 Months Ended				9M FY 25 (Unaudited)	9M FY 24 (Unaudited)	Year Ended 31.03.2025 (Audited)
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)			
	Income From Operations							
1	Revenue from Operations	116.31	186.59	342.33	482.33	810.29	1,036.04	
	Total revenue from operations	116.31	186.59	342.33	482.33	810.29	1,036.04	
2	Other Income	(0.00)	1.60	0.03	5.09	0.33	41.85	
3	Total Revenue (1+2)	116.31	188.19	342.36	487.42	810.62	1,077.90	
4	Expenses							
a	Cost of material consumed	69.57	60.12	158.11	230.83	477.87	601.23	
b	Changes in inventories of finished goods work in progress and stock-in-Trade	(10.28)	38.16	56.06	18.13	(9.61)	(17.86)	
c	Employee Benefit Expenses	26.82	45.83	59.26	117.75	159.69	230.42	
d	Finance Costs	9.43	16.01	4.31	30.66	10.55	23.31	
e	Depreciation and Amortisation Expenses	44.02	46.84	63.67	138.82	140.19	186.31	
f	Other Expenses	142.41	55.68	70.69	246.30	302.72	367.44	
	Total Expenses	281.97	262.64	412.10	782.49	1,081.41	1,392.83	
5	Profit before tax (3-4)	(165.66)	(74.45)	(69.74)	(295.07)	(270.79)	(314.93)	
6	Tax Expenses	-	-	-	-	-	-	
	Current Taxes	-	-	-	-	-	-	
	Deferred Taxes	-	-	-	-	-	-	
7	Profit for the period Year (5-6)	(165.66)	(74.45)	(69.74)	(295.07)	(270.79)	(314.93)	
8	Other Comprehensive income	-	-	-	-	-	-	
	Items that will not be reclassified to profit or loss, net of tax	-	-	-	-	-	-	
	Items that will be reclassified to profit or loss, net of tax	-	-	-	-	-	-	
	Total other comprehensive income (7+8)	(165.66)	(74.45)	(69.74)	(295.07)	(270.79)	(309.16)	
9	Total comprehensive income (7+8)	(165.66)	(74.45)	(69.74)	(295.07)	(270.79)	(309.16)	
10	Paid up Equity Share Capital	165.83	165.83	165.83	165.83	165.83	165.83	
11	Other equity	-	-	-	-	-	-	
12	Earnings per Share (Before Extraordinary Items) (of Rs2/- each)	(a) Basic (b) Diluted	(2.00) (1.94)	(0.90) (0.87)	(0.84) (0.82)	(3.56) (3.45)	(3.27) (3.17)	(3.80) (3.69)

NOTES:

- The above standalone financial results of Vivimed Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on March 13 2026. The statutory auditors of the Company have carried out a limited review on standalone financial results and expressed a modified conclusion thereon.
- These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("IND AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- Total Debt availed from SBI Bank has been assigned to Rare Asset Reconstruction Company (ARC) under SARFAESI Act, 2002. The liability continues to be shown under Borrowing and is payable to RARE ARC.
- Deferred tax will be calculated at the end of year.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.



For VIVIMED LABS LIMITED
(SANTOSH VARADWAR)
MANAGING DIRECTOR

Place : Hyderabad
Date : 13.03.2026

VIVIMED LABS LIMITED
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2025

Rs in Million

Sl. No.	Particulars	3 Months Ended					Year Ended 31.03.2025
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	
	Income From Operations						
1	Revenue from operations	159.89	206.12	365.10	579.89	906.55	1,162.69
	Total revenue from operations	159.89	206.12	365.10	579.89	906.55	1,162.69
2	Other Income	0.00	2.12	0.67	5.72	1.54	43.71
3	Total Revenue (1+2)	159.89	208.25	365.77	585.61	908.09	1,206.40
4	Expenses						
a	Cost of material consumed	89.36	53.02	147.14	250.01	500.02	577.61
b	Changes in inventories of finished goods work in progress and stock-in-Trade	(10.28)	38.16	49.73	18.13	(15.94)	20.92
c	Employee Benefit Expenses	36.95	55.96	72.94	149.96	196.07	283.94
d	Finance Costs	10.04	16.55	4.83	32.23	12.07	29.47
e	Depreciation and Amortisation Expenses	46.28	49.04	66.15	145.45	147.24	202.24
f	Other Expenses	153.18	68.53	84.73	283.32	322.24	410.20
	Total Expenses	325.83	281.26	425.32	879.10	1,171.70	1,524.88
5	Profit before tax (3-4)	(165.94)	(73.01)	(59.75)	(293.49)	(263.61)	(318.48)
6	Prior Period Expenses	-	-	-	-	-	-
7	Tax expenses	-	-	-	-	-	2.26
	Current Taxes	-	-	-	-	-	-
	Deferred Taxes	-	-	-	-	-	(1.13)
	Total tax expenses	-	-	-	-	-	1.13
7	Profit for the period/Year before non-controlling interest (5-6)	(165.94)	(73.01)	(59.75)	(293.49)	(263.61)	(319.61)
8	Non-controlling interest	-	-	-	-	-	-
9	Profit for the period/year (7-8)	(165.94)	(73.01)	(59.75)	(293.49)	(263.61)	(319.61)
10	Other comprehensive income items that will not be reclassified to profit or loss, net of tax items that will be reclassified to profit or loss, net of tax	-	-	-	-	-	4.24
	Total other comprehensive income	-	-	-	-	-	4.63
11	Non-controlling interest	-	-	-	-	-	4.63
12	Other comprehensive income attributable to shareholders (10+11)	-	-	-	-	-	-
	Total comprehensive income attributable to:						
	Shareholders of the Company	(165.94)	(73.01)	(59.75)	(293.49)	(263.61)	(314.98)
	Non-controlling interest	-	-	-	-	-	-
	Total Comprehensive Income	(165.94)	(73.01)	(59.75)	(293.49)	(263.61)	(314.98)
13	Paid up Equity Share Capital	165.83	165.83	165.83	165.83	165.83	165.83
14	Other equity	-	-	-	-	-	-
15	Earnings per Share (before Extraordinary Items) (9/RS2/- each) (not annualised)						
(a)	Basic	(2.00)	(0.88)	(0.72)	(3.54)	(3.18)	(3.85)
(b)	Diluted	(1.94)	(0.85)	(0.70)	(3.44)	(3.09)	(3.74)

NOTES:

1. The above unaudited consolidated financial results of Vivimed Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on March 13, 2026. The statutory auditors of the Company have carried out a limited review on consolidated financial results and expressed a modified conclusion thereon.

2. These consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("IND AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").

3. Total Debt availed from SBI Bank has been assigned to Rare Asset Reconstruction Company (ARC) under SAFEVEST Act, 2002. The liability continues to be shown under Borrowing and is payable to RARE ASSET RECONSTRUCTION COMPANY.

4. Deferred tax will be calculated at the end of year.

5. Corresponding numbers of previous period/year have been regrouped, wherever necessary.


For VIVIMED LABS LIMITED
 (SANTOSH K. RAJAWAR)
 MANAGING DIRECTOR



Independent Auditor's Review Report on the Quarterly Unaudited Standalone financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review report to
The Board of Directors
Vivimed Labs Limited**

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of **Vivimed Labs Limited** ("the Company"), for the Quarter 31st December 2025 ('the statement'), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015 as amended from time to time ("the Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing and consequently does not enable us to obtain assurance that we would be aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. **Basis for Qualified Conclusion**
 - i. Based on information provided to us by the management, Vivimed Labs Limited has not provided for interest, penal interest and penal charges approximately amounting to ₹ 164.52 million on an accrual basis for the Quarter ended 31.12.2025, (₹ 472.37 million for the year to date 31.12.2025) pertaining to loans. [Term Loans and Working capital Loans]. Meanwhile, we are in the process of obtaining direct balance confirmation from the banks. This omission results in an understatement of liabilities and losses for the reporting period, thereby deviating the accrual principle as mandated by Indian accounting standards.



- ii. An extract of forensic audit report relating to certain transactions of earlier financial years, conducted during the FY 2022-23 is received by us during the current period. We are presently in the process of evaluating the observations and assessing the possible financial impact, if any. Pending completion of such evaluation, no adjustments have been made in the current financial results.
- iii. The Company has recognized a provision for commission expenses amounting to ₹ 46.03 million relating to sales of earlier financial years based on proforma invoices. As at the reporting date, the Company is in the process of obtaining supporting documents, confirmations and other relevant documentation to substantiate the existence and measurement of the obligation.

In the absence of sufficient appropriate audit evidence available to us at this stage to fully evaluate the recognition of the said provision in accordance with Ind AS 37 - Provisions, Contingent Liabilities and Contingent Assets, we are unable to determine whether any adjustment may be necessary in respect of the provision recognized and the corresponding impact on the financial results.

5. Qualified Conclusion

Based on our review, with the exception of the matter described in the preceding paragraph, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid 'Ind AS 34' Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SVRL & Co.

Chartered Accountants

Firm's Regn No: 016182S



Ramakrishna

Partner

M. No. 213487

Place: Hyderabad

Date: 13-03-2026

UDIN: 26213487KPKITO5979

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Vivimed Labs Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Vivimed Labs Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), and its associates for the Quarter Ended 31st December 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master circular issued by SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Holding Company
Vivimed Labs Limited

Subsidiaries

1. Finoso Pharma Private Limited
2. Vivimed Holdings Limited
3. Vivimed Labs USA INC



4. Vivimed Labs Mauritius Limited

Associates

1. Yantra Green Power Private Limited

5. Basis for Qualified Conclusion

- i. Based on information provided to us by the management, Vivimed Labs Limited has not provided for interest, penal interest and penal charges approximately amounting to ₹ 164.52 million on an accrual basis for the Quarter ended 31.12.2025, (₹ 472.37 million for the year to date 31.12.2025) pertaining to loans. [Term Loans and Working capital Loans]. Meanwhile, we are in the process of obtaining direct balance confirmation from the banks. This omission results in an understatement of liabilities and losses for the reporting period, thereby deviating the accrual principle as mandated by Indian accounting standards.
- ii. An extract of forensic audit report relating to certain transactions of earlier financial years, conducted during the FY 2022-23 is received by us during the current period. We are presently in the process of evaluating the observations and assessing the possible financial impact, if any. Pending completion of such evaluation, no adjustments have been made in the current financial results.
- iii. The Company has recognized a provision for commission expenses amounting to ₹ 46.03 million relating to sales of earlier financial years based on proforma invoices. As at the reporting date, the Company is in the process of obtaining supporting documents, confirmations and other relevant documentation to substantiate the existence and measurement of the obligation.

In the absence of sufficient appropriate audit evidence available to us at this stage to fully evaluate the recognition of the said provision in accordance with Ind AS 37 - Provisions, Contingent Liabilities and Contingent Assets, we are unable to determine whether any adjustment may be necessary in respect of the provision recognized and the corresponding impact on the financial results.

6. Qualified Conclusion

Based on our review, with the exception of the matter described in the preceding paragraph, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. Other Matters:

The unaudited consolidated financial results includes the interim financial information of 4 subsidiaries which have not been reviewed by their auditors, whose interim financial information



reflect total revenue of ₹ 43.57 million for the quarter ended December 31, 2025, total loss after tax (net) of ₹ 0.12 million for the quarter ended December 31, 2025 as considered in the Statement.

These unaudited interim financial results and other unaudited financial information have been approved and furnished to us by the Management and our conclusion on "the Statement", in so far as it relates to the affairs of subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information.

Our conclusion on "the Statement" in respect of matters stated above is not modified with respect to our reliance on the financial results certified by the Management.

For SVRL & Co.

Chartered Accountants

Firm's Regn No: 016182S



G Ramakrishna

Partner

M. No. 213487

Place: Hyderabad

Date: 13-03-2026

UDIN: 26213487BBQQJ5970